Trial · NCT00093015
Results by group22
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 22
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Time to All-cause Mortality or Cardiovascular (CV) Events Including Hospitalization Due to Acute Myocardial Ischemia, Congestive Heart Failure (CHF), Myocardial Infarction (MI), and Cerebrovascular Accident (CVA) | Placebo | 602 | Participants | ||
Time to All-cause Mortality or Cardiovascular (CV) Events Including Hospitalization Due to Acute Myocardial Ischemia, Congestive Heart Failure (CHF), Myocardial Infarction (MI), and Cerebrovascular Accident (CVA) | Darbepoetin Alfa | 632 | Participants | ||
| Time to All-cause Mortality or End Stage Renal Disease (ESRD) | Placebo | 618 | Participants | ||
| Time to All-cause Mortality or End Stage Renal Disease (ESRD) | Darbepoetin Alfa | 652 | Participants | ||
| Time to All-cause Mortality | Placebo | 395 | Participants | ||
| Time to All-cause Mortality | Darbepoetin Alfa | 412 | Participants | ||
| Time to Cardiovascular Mortality | Placebo | 250 | Participants | ||
| Time to Cardiovascular Mortality | Darbepoetin Alfa | 259 | Participants | ||
| Time to Myocardial Infarction | Placebo | 129 | Participants | ||
| Time to Myocardial Infarction | Darbepoetin Alfa | 124 | Participants | ||
| Time to Cerebrovascular Accident | Placebo | 53 | Participants | ||
| Time to Cerebrovascular Accident | Darbepoetin Alfa | 101 | Participants | ||
| Time to Congestive Heart Failure | Placebo | 229 | Participants | ||
| Time to Congestive Heart Failure | Darbepoetin Alfa | 205 | Participants | ||
| Time to End Stage Renal Disease | Placebo | 330 | Participants | ||
| Time to End Stage Renal Disease | Darbepoetin Alfa | 338 | Participants | ||
| Rate of Decline in Estimated Glomerular Filtration Rate (eGFR) Relative to Baseline | Placebo | -1.89 | Standard Deviation 10.60 | mL/min/1.73m^2 | |
| Rate of Decline in Estimated Glomerular Filtration Rate (eGFR) Relative to Baseline | Darbepoetin Alfa | -1.30 | Standard Deviation 10.81 | mL/min/1.73m^2 | |
| Change in Patient Reported Fatigue Relative to Baseline at Week 25 | Placebo | 2.8 | Standard Deviation 10.3 | Units on a scale | |
| Change in Patient Reported Fatigue Relative to Baseline at Week 25 | Darbepoetin Alfa | 4.2 | Standard Deviation 10.5 | Units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00093015/results